Dr Ferrer is an allergology specialist at the Clinica Universidad de Navarra. She graduated in Medicine and Surgery from the University of Zaragoza and was awarded her doctorate in Medicine by the University of Navarra. Dr Ferrer carried out her postdoctoral training in the Allergy Division at the State University of New York and worked in the Pulmonary, Allergy and Critical Care Division at the Medical University of South Carolina where she stayed until she began her work at the Clínica. Dr Ferrer is Harvard Macy scholar from the Harvard Medical School.
She dedicates her work and research to studying the physiopathology of chronic urticaria and has received several grants from the Spanish National Health Department. She is now running two nationwide, multicentre clinical trials (Efficacy and Safety Study of Omalizumab (Xolair®)) to treat Chronic Urticaria (ClinicalTrials.gov Identifier: NCT01713725) and Efficacy Study of Omalizumab in Cholinergic Urticaria (ClinicalTrials.gov Identifier: NCT02012387). Dr Ferrer also researches new forms of oral immunotherapy and has a research grant project from the National Ministry of research, development and innovation for developing nanoparticles for oral peanut immunotherapy.
Dr Ferrer is the co-author of two international patents on immunotherapy with nanotechnology and has written more than 70 articles in international journals and 6 book chapters. She is a member of the Spanish Allergy Society Skin Committee, EAACI and the AAAAI Dermatology section.